Talzenna News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Talzenna. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Talzenna Today - Breaking & Trending Today

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma. ....

United States , James Isaacs , Department Of Hematology , Medical Oncology , Cleveland Clinic , Cleveland Clinic Gross Family Melanoma Registry , Nivolumab Plus Talazoparib , Aacr Annual Meeting ,

Pfizer : FDA Approves Talzenna-Xtandi Combination To Treat Prostate Cancer

Pfizer (PFE) said that the U.S. Food and Drug Administration has approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), for the treatment of adult patients with homologous recombination repair or HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). ....

European Medicines Agency , Drug Administration , More Such Health News , European Medicines , Prostate Cancer , Fda Approval , Health News ,

Pfizer Reports Positive Data From Phase 3 Trial Of Talzenna/Xtandi Combo

NEW YORK CITY (dpa-AFX) - Pfizer (PFE) Thursday reported positive results from the Phase 3 TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with ....

Dennis Riedl , Drug Administration , Priority Review ,

Pfizer Reports Positive Data, Priority Review for Talzenna/Xtandi Combo

By Colin Kellaher

Pfizer Inc. on Thursday said a Phase 3 study combining its breast-cancer drug Talzenna with its prostate-cancer drug Xtandi showed a 37% reduction in the risk of disease. | February 16, 2023 ....

New York , United States , Colin Kellaher , Pfizer Inc , Drug Administration , Dow Jones , Nc Stock Exchange , Press Release , F Pfe Us7170811035 ,

Pfizer Reports Positive Topline Results From Phase 3 TALZENNA Trial

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced Tuesday positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib) plus XTANDI in men with metastatic castration-resistant ....

Chris Boshoff , Pfizer Inc , Pfizer Global Product Development , More Such Health News , Chief Development Officer , Rare Disease ,